KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Intangibles (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 12 years of Intangibles data on record, last reported at $4.8 billion in Q4 2024.

  • For Q4 2024, Intangibles rose 531.99% year-over-year to $4.8 billion; the TTM value through Dec 2024 reached $4.8 billion, up 531.99%, while the annual FY2024 figure was $4.8 billion, 531.99% up from the prior year.
  • Intangibles reached $4.8 billion in Q4 2024 per JAZZ's latest filing, down from $5.2 billion in the prior quarter.
  • Across five years, Intangibles topped out at $5.8 billion in Q1 2023 and bottomed at $1.0 million in Q3 2021.
  • Average Intangibles over 4 years is $2.7 billion, with a median of $2.2 billion recorded in 2020.
  • The widest YoY moves for Intangibles: up 531.99% in 2024, down 9.17% in 2024.
  • A 4-year view of Intangibles shows it stood at $2.2 billion in 2020, then plummeted by 99.95% to $1.0 million in 2021, then skyrocketed by 75150.0% to $752.5 million in 2023, then surged by 531.99% to $4.8 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Intangibles were $4.8 billion in Q4 2024, $5.2 billion in Q1 2024, and $752.5 million in Q4 2023.